Avenue Therapeutics, Inc. (ATXI) |
| 0.626 -0.004 (-0.63%) 01-14 12:31 |
| Open: | 0.6261 |
| High: | 0.6261 |
| Low: | 0.626 |
| Volume: | 3 |
| Market Cap: | 2(M) |
| PE Ratio: | 0.81 |
| Exchange: | NASDAQ Capital Market |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 0.97 |
| Resistance 1: | 0.87 |
| Pivot price: | 0.78 |
| Support 1: | 0.71 |
| Support 2: | 0.59 |
| 52w High: | 2.06 |
| 52w Low: | 0.1653 |
Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain. The company was incorporated in 2015 and is based in New York, New York.
Financials
| EPS | 2.580 |
| Book Value | 1.330 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.000 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | 0.00 |
| Return on Assets (ttm) | 0.0 |
| Return on Equity (ttm) | 0.0 |
Company news
Tue, 13 Jan 2026
Avenue Therapeutics shareholders elect directors, ratify KPMG auditor - MSN
Tue, 30 Dec 2025
ATXI: All directors were elected and KPMG LLP was ratified as auditor for 2025 - TradingView — Track All Markets
Thu, 06 Nov 2025
Avenue Therapeutics Announces Acquisition of Subsidiary Baergic Bio by Axsome Therapeutics - GlobeNewswire
Fri, 14 Mar 2025
Avenue Therapeutics Inc erwartet einen Verlust von 57 Cents pro Aktie - Earnings Preview - TradingView — Track All Markets
Fri, 29 Nov 2024
Avenue Therapeutics faces Nasdaq delisting over equity shortfall - Investing.com
Thu, 14 Nov 2024
Avenue Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights - GlobeNewswire
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
